Demonstrates effective microbial inactivation in ballast water, indicating a vital port biosecurity enhancement.
To address the risks of cross-border transmission of pathogenic microorganisms posed by the failure or non-compliance of shipboard ballast water treatment systems, ports urgently require efficient and flexible emergency response solutions. This study presents a novel, containerized, integrated ship-to-shore emergency response system specifically designed for the rapid inactivation of pathogenic microorganisms in ballast water. The core innovation lies in the integration of a three-degree-of-freedom (3-DOF) hydraulic robotic arm, a vision and positioning system, and a dynamic inflatable sealing structure designed for rapid, automated docking with a ship’s ballast water discharge outlet (DN250), thereby enhancing operational safety and efficiency. The system employs a purely physical treatment process of “ultrasound (US) pre-treatment + dual-stage ultraviolet (UV) disinfection,” allowing for reception and treatment without secondary chemical pollution. The integrated treatment train, consisting of US (30 kHz, 7.6–12 kW, minimum acoustic energy density ≥ 0.45 J/cm2) followed by dual-stage UV disinfection (minimum UV dose: 147 mJ/cm2), maintained effective microbial inactivation at turbidity levels of 15, 125, 250, and 500 NTU. US alone showed little direct bactericidal effect, whereas the first UV stage achieved log reduction values (LRVs) of 3.31–4.13, and the complete US + UV + UV process achieved total LRVs of 5.07–7.34 for Escherichia coli. The results showed that dual-stage UV disinfection was key to achieving high inactivation efficacy (p < 0.001), while ultrasound, despite its limited direct bactericidal effect, may have facilitated downstream UV disinfection within the sequential treatment train. This system not only fills a critical gap in port biosecurity emergency infrastructure but also provides an experimentally validated, efficient, environmentally friendly, and flexibly deployable shore-based solution.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: